Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 28

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 28
---
 of these
provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering. However, if certain events
occur prior to the end of such five-year period, including if we become a “large accelerated filer,” our annual gross revenue
exceeds $1.07 billion or we issue more than $1.0 billion of non-convertible debt in any three-year period, we will cease to be an emerging
growth company prior to the end of such five-year period.

We have elected to take advantage
of certain of the reduced disclosure obligations in this prospectus and may elect to take advantage of other reduced reporting requirements
in future filings. As a result, the information that we provide to our stockholders may be different from what you might receive from
other public reporting companies in which you hold equity interests.

In addition, under the JOBS
Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private
companies.

We are also a “smaller
reporting company,” as that term is defined in Rule 12b-2 under the Exchange Act. As a result, many of the same exemptions from
reporting requirements available to us as an emerging growth company are also available to us as a smaller reporting company, including
not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act and reduced disclosure
obligations regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease
to qualify as an emerging growth company, those exemptions may continue to be available to us.

Corporate Information

Our principal executive offices
are located at 1200 Prospect Street, Suite 525, La Jolla, California 92037. Our telephone number is (858) 964-3720. We maintain an Internet
website at www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of this prospectus.
We have included our website address in this prospectus as an inactive textual reference only and not as an active hyperlink.

<div align='center'>4

RISK FACTORS</div>

Investing in our securities
involves a high degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other
factors described in our most recent Annual Report on Form 10-K, as supplemented and